# A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients

> **NCT02448914** · PHASE1 · COMPLETED · sponsor: **LobSor Pharmaceuticals AB** · enrollment: 11 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** TRIGEL
- **DRUG:** Duodopa

## Key facts

- **NCT ID:** NCT02448914
- **Lead sponsor:** LobSor Pharmaceuticals AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2016-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02448914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02448914, "A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02448914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*